Discovery of bepridil as a valuable lead compound with potent p53-MDM2 inhibitory activity / 药学实践杂志

Objective To find novel lead compounds as p53-MDM2 inhibitors by drug repurposing strategy. Methods The p53-MDM2 inhibitory activities of compounds were determined by FP and western blotting. MTT method was used to determine the in-vitro antitumor activities. The metabolites in human liver microsomes were tested. Results Bepridil showed excellent in-vitro anti-tumor activity and strong p53-MDM2 protein binding inhibitory activity, which can significantly reduce the expression of MDM2 protein in a dose-dependent manner. The metabolites in human liver microsomes are mainly benzene ring hydroxyl mono-oxidation metabolites. Conclusion Bepridil can be used as a lead compound for p53-MDM2 protein binding small molecule inhibitors for subsequent structural optimization design studies.

Research progress of p53-MDM2/MDM4 related anti-tumor drugs and their mechanisms / 中国肿瘤生物治疗杂志

@#[摘 要] 由抑癌基因TP53编码的p53是体内最重要的抑癌因子之一。MDM2/MDM4是p53的负向调控因子，通过p53-MDM2/MDM4负反馈环路调控p53功能。几乎所有肿瘤均存在p53异常，主要包括p53突变和MDM2/MDM4扩增引起的p53失活。p53相关药物研发一直是肿瘤研究中的热点，然而，直到最近10年才研发出相对成熟的药物。目前，以逆转p53失活为目标的药物研发存在以下几种设计思路：（1）诱导突变p53恢复野生型功能，如PRIMA-1/PRIMA-1MET、COTI-2；（2）促进突变p53降解，如Ganetespib、伏立诺他；（3）阻断MDM2/MDM4，如RG7388、ALRN-6924等。上述药物均已进入临床试验，其中伏立诺他、PRIMA-1MET和ALRN-6924已分别在卵巢癌及骨髓增生异常综合征、皮肤T细胞淋巴瘤、急性髓系白血病中取得较好的疗效。进一步阐明p53-MDM2/MDM4环路异常在肿瘤中的作用机制，对于未来研发p53相关抗肿瘤药物以及指导临床用药具有重要意义。

Molecular mechanism of miR-221 promoting apoptosis of human retinal vascular endothelial cells induced by high glucose by regulating p53/MDM2 signaling pathway / 国际眼科杂志(Guoji Yanke Zazhi)

@#AIM: To study the effect of miR-221 on apoptosis of high glucose-induced human retinal vascular endothelial cells and to explore its mechanism. <p>METHODS: High-glucose-induced HRCECs were established by treatment of HRCECs cells with glucose at 30mmol/L for 48h; HG+miR-NC group(transfected miR-NC), HG+miR-221 group(transfected miR-221 mimics), HG+anti-miR-NC group(transfected anti-miR-NC), HG+anti-miR-221 group(transfected anti-miR-221), HG+miR-221+pcDNA 3.1 group(co-transfected miR-221 mimics and pcDNA 3.1), HG+miR-221+pcDNA 3.1-MDM2 group(co-transfected miR-221 mimics and pcDNA 3.1-MDM2), transfected into HRCECs cells by liposome method, and then treated with high glucose; qRT-PCR method for detection the expression of miR-221, p53 and MDM2; the protein expression of p53 and MDM2 were detected by Western blot. The apoptosis of cells was detected by flow cytometry. <p>RESULTS: Compared with NG group, the expression of miR-221 and p53 was significantly increased, the expression of MDM2 was significantly decreased, and the apoptosis rate was significantly increased in high glucose-induced HRCECs. Overexpression of miR-221 induced apoptosis of high glucose-induced HRCECs cells is more obvious. Inhibition of miR-221 can down-regulate the apoptosis of high glucose-induced HRCECs and down-regulate p53, up-regulate MDM2; overexpression of MDM2 can reverse the inhibition by miR-221 anti-apoptotic effect of cells and regulation of p53 and MDM2 of high-glucose-induced HRCECs. <p>CONCLUSION: miR-221 can promote the apoptosis of high-glucose-induced human retinal vascular endothelial cells, and its mechanism is related to p53/MDM2 signaling pathway.

Research progress of inhibitors of peptides and peptidomimetic acting on P 53-MDM2 i nte rf ace / 药学实践杂志

Tumor diseases have attracted great attention of the society because of the increasing morbidity in recent years .To inhibit the P53-MDM2 interaction has become an important target for design of cancer drug ,and a lot of peptide and small molecule inhibitors have been found with various kinds of drug screening and research tools .This paper summarized the recent progress of the peptide and peptidomimetic inhibitors of P53-MDM2 at home and abroad lately .

Research progress on drugs targeting p53 / 中国药理学通报

With the understanding of the development and pro-gress of the cancer,the research of targeted cancer drug devel-opment reaches into a new era.p53 is an important tumor sup-pressor gene,the protein coded by p53 plays a critical role in tumor suppression mainly by inducing cell cycle regulation, DNA repair and apoptosis.Nowadays,p53 becomes a relatively attractive target for anti-cancer drug development and there are some drugs targeting p53,moreover,APR-246 which targets mutant p53 is in Phase II clinical trial.In addition,it facilitates drugs discovery programmes in the challenging area of protein-protein interactions and mutant protein conformational change. The review discusses the research progress of drugs which target p53 and elucidates the characteristics and mechanisms of these compounds.